Home
About Us
Membership
Member Biography

Member Biography

Tareq Salous, MD

Tareq Salous, MD

Phone: (317) 948-6942
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 439
Indianapolis, IN 46202

Appointments

Assistant Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate member, Experimental and Developmental Therapeutics

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerCTO-A032103

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04ACTO-MK-3475-04A

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 AlterationsCTO-LOXO-FG3-22001

Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder: HCRN GU22-598CTO-HCRN-GU22-598

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.CTO-J4G-MC-JZVD

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid TumorsCTO-LOXO-LNC-24001

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209)CTO-7465-CL-0209

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered with Enfortumab Vedotin and Pembrolizumab in Participants with Advanced Urothelial CancerCTO-GB-4362-101

#ResearchCuresCancer

Support Our Research